Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Oncofertility
  • Reduced price
Veterinary Psychopharmacology

Veterinary Psychopharmacology

9781119226222
642.29 zł
578.06 zł Save 64.23 zł Tax included
Lowest price within 30 days before promotion: 578.06 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

Offers an updated second edition of the comprehensive reference on the use of drugs for veterinary mental health care and behavior modification

This fully revised Second Edition of Veterinary Psychopharmacology offers an authoritative reference to the drugs prescribed to treat psychiatric, psychological, and behavioral disorders in pets. Designed to be an accessible resource, the text is divided into sections on psychopharmacologic principles and clinical psychopharmacology. Comprehensive in scope, the book contains detailed information on pharmacologic intervention for pet mental health and behavior issues, offers thorough explanations of options, and explores why a particular drug should be prescribed and why it works.

Updated to include the recent advances in psychopharmacology for pets, the Second Edition includes new chapters that cover the principles of psychopharmacology, miscellaneous serotonergic agents, anticonvulsants and mood stabilizers, sympatholytic agents, and NMDA antagonists. In addition, the text explains the drug options, including all the information necessary to correct dysfunctions in the brain’s chemistry through pharmacologic treatment. This important resource::

  • Presents an updated and comprehensive resource for pharmacologic treatments for pet, equine, and zoo animal psychiatric disorders and behavior problems
  • Contains in-depth information on drugs that promote neurochemical changes that will alter the mood, emotional state, reactivity, and behavior of the patient, including prescribing options and mechanisms of action
  • Includes new chapters on the principles of psychopharmacology, miscellaneous serotonergic agents, mood stabilizers, sympatholytic agents, and NMDA antagonists

Written for veterinarians, veterinary behaviorists, and veterinary students, the updated second edition of Veterinary Psychopharmacology is a complete source for current knowledge on pharmacologic behavior modification.

“Overall, this book packs a substantial amount of useful data into approximately 300 pages. The scope of the book is comprehensive and may include more in-depth information than casual prescribers seek, but it will be a good resource for the practitioners who are interested in immersing themselves into veterinary psychopharmacology.” - JAVMA Vol 255 No. 6

Product Details
John Wiley and Sons
78325
9781119226222
9781119226222

Data sheet

Publication date
2019
Issue number
2
Cover
hard cover
Pages count
336
Dimensions (mm)
180.00 x 261.00
Weight (g)
868

  • Contributors xxi

    Preface xxiii

    Acknowledgments xxv

    Part I Principles of Veterinary Psychopharmacology 1

    1 General Principles of Psychopharmacology 3
    Thomas F. Murray

    Drug Action 3

    Dose Dependence of Drug Interaction with Receptors 4

    Structural Features of the Central Nervous System (CNS) and Neurotransmission 5

    Biogenic Amine Neurotransmitters and Affective Disorders 8

    2 Amino Acid Neurotransmitters: Glutamate, GABA, and the Pharmacology of Benzodiazepines 11
    Thomas F. Murray

    Introduction 11

    Glutamatergic Synapses 11

    Pharmacology of Ketamine and Tiletamine 14

    GABAergic Synapses 15

    3 Biogenic Amine Neurotransmitters: Serotonin 21
    Thomas F. Murray

    Introduction 21

    The Biogenic Amines 21

    Serotonin 22

    4 Biogenic Amine Transmitters: Acetylcholine, Norepinephrine, and Dopamine 29
    Thomas F. Murray

    Acetylcholine 29

    Norepinephrine 32

    Dopamine 37

    5 Neuropeptides: Opioids and Oxytocin 43
    Thomas F. Murray

    Introduction 43

    Endogenous Opioid Peptides 43

    Oxytocin 47

    Part II Practice of Veterinary Psychopharmacology 51

    6 Introduction to Clinical Psychopharmacology for Veterinary Medicine 53
    Sharon L. Crowell-Davis and Leticia Mattos de Souza Dantas

    Introduction 53

    Prescribing in the United States: The Animal Medicinal Drug Use Clarification Act (AMDUCA 1994) 54

    Cost 55

    Drug Selection 56

    Medicating the Patient 57

    Competition Animals 58

    Taking the Behavioral History 58

    The Behavioral Exam 63

    Duration of Treatment 63

    Limitations 64

    7 Benzodiazepines 67
    Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis

    Action 67

    Overview of Indications 67

    Contraindications, Side Effects, and Adverse Events 69

    Overdose 69

    Clinical Guidelines 69

    Specific Medications 71

    I. Alprazolam 71

    II. Chlordiazepoxide HC1 73

    IV. Clorazepate Dipotassium 78

    V. Diazepam 80

    VI. Flurazepam Hydrochloride 86

    VII. Lorazepam 87

    VIII. Oxazepam 89

    IX. Triazolam 91

    8 Selective Serotonin Reuptake Inhibitors 103
    Niwako Ogata, Leticia Mattos de Souza Dantas, and Sharon L. Crowell-Davis

    Action 103

    Overview of Indications 103

    Contraindications, Side Effects, and Adverse Events 104

    Adverse Drug Interactions 104

    Overdose 105

    Clinical Guidelines 105

    Specific Medications 106

    I. Citalopram Hydrobromide 106

    II. Fluoxetine Hydrochloride 108

    III. Fluvoxamine 115

    IV. Paroxetine Hydrochloride 117

    V. Sertraline Hydrochloride 119

    VI. Escitalopram Oxalate 122

    9 Miscellaneous Serotonergic Agents 129
    Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis

    Introduction 129

    Azapirones 129

    Action 129

    Overview of Indications 129

    Contraindications, Side Effects, and Adverse Events 129

    Adverse Drug Interactions 129

    Overdose 129

    Clinical Guidelines 129

    Specific Medications 130

    I. Buspirone 130

    I. Trazodone Hydrochloride 135

    10 Anticonvulsants and Mood Stabilizers 147
    Sharon L. Crowell-Davis, Mami Irimajiri, and Leticia Mattos de Souza Dantas

    Action 147

    Overview of Indications 148

    Clinical Guidelines 148

    Specific Medications 148

    I. Carbamazepine 148

    II. Gabapentin 149

    III. Pregabalin 152

    11 Sympatholytic Agents 157
    Niwako Ogata and Leticia Mattos de Souza Dantas

    Action 157

    Overview of Indications 157

    Contraindications, Side Effects, and Adverse Events 158

    Overdose 159

    Clinical Guidelines 159

    Specific Medications 160

    I. Clonidine 160

    II. Detomidine 161

    III. Dexmedetomidine 163

    IV. Propranolol 165

    12 N-Methyl-D-Aspartate (NMDA) Receptor Antagonists 171
    Niwako Ogata and Leticia Mattos de Souza Dantas

    Action 171

    Overview of Indications 172

    Contraindications/ Side Effects, and Adverse Events 172

    Clinical Guidelines 173

    Specific Medications 173

    I. Dextromethorphan 173

    II. Amantadine 175

    III. Memantine 176

    IV. Huperzine A 179

    13 Monoamine Oxidase Inhibitors 185
    Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis

    Action 185

    Overview of Indications 186

    Specific Medications 186

    I. Selegiline Hydrochloride 186

    14 Antipsychotics 201
    Lynne Seibert and Sharon Crowell-Davis

    Introduction 201

    Action 201

    Overview of Indications 202

    General Pharmacokinetics 203

    Contraindications, Side Effects, and Adverse Events 203

    Overdose 203

    Clinical Guidelines 204

    Specific Medications 204

    I. Acepromazine Maleate 204

    II. Azaperone 206

    III. Chlorpromazine 206

    IV. Clozapine 207

    V. Fluphenazine 208

    VI. Haloperidol 209

    VII. Pimozide 210

    VIII. Promazine 211

    IX. Sulpiride 211

    X. Thioridazine 212

    15 CNS Stimulants 217
    Sharon L. Crowell-Davis

    Action 217

    Overview of Indications 217

    Contraindications, Side Effects, and Adverse Events 217

    Adverse Drug Interactions 217

    Overdose 217

    Clinical Guidelines 218

    Specific Medications 219

    I. Amphetamine 219

    II. Atomoxetine HCl 221

    III. Methylphenidate Hydrochloride 223

    16 Tricyclic Antidepressants 231
    Sharon L. Crowell-Davis

    Action 231

    Overview of Indications 231

    Contraindications, Side Effects, and Adverse Events 232

    Adverse Drug Interactions 232

    Overdose 232

    Discontinuation 233

    Clinical Guidelines 233

    Specific Medications 233

    I. Amitriptyline 233

    II. Clomipramine Hydrochloride 236

    III. Desipramine 243

    IV. Doxepin 244

    V. Imipramine 246

    VI. Nortriptyline 248

    17 Opioids and Opioid Antagonists 257
    Leticia Mattos de Souza Dantas and Sharon L. Crowell-Davis

    Action 257

    Overview of Indications 257

    Contraindications, Side Effects, and Adverse Events 258

    Clinical Guidelines 258

    Specific Medications 258

    I. Nalmefene 258

    II. Naloxone HCl 260

    III. Naltrexone Hydrochloride 261

    IV. Pentazocine 264

    18 Hormones 269
    Sharon L. Crowell-Davis

    Introduction 269

    Oxytocin 270

    Clinical Pharmacology 270

    Indications 270

    Side Effects 270

    Doses in Nonhuman Animals 270

    Effects Documented in Nonhuman Animals 270

    Progestins 270

    Action 270

    Overview of Indications 271

    Contraindications, Side Effects, and Adverse Events 271

    Overdose 271

    Clinical Guidelines 272

    Specific Medications 272

    I. Medroxyprogesterone Acetate (MPA) 272

    II. Megestrol Acetate 273

    19 Combinations 281
    Leticia Mattos de Souza Dantas, Sharon L. Crowell-Davis, and Niwako Ogata

    Introduction 281

    Overview of Drug Augmentation 281

    Potentially Beneficial Combinations 282

    Adverse Interactions and Contraindications 283

    Changing and Weaning Patients off Medications 285

    Cytochrome P450 (CYP) 285

    Interactions That Can Affect Dosing 285

    Algorithms: Possible Future Direction 286

    Conclusion 288

    Index 291

Comments (0)